Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jun 11;14(2):832-837.
doi: 10.1159/000516271. eCollection 2021 May-Aug.

Oxaliplatin-Associated Amaurosis Fugax

Kimitoshi Kubo  1 , Noriko Kimura  2 , Ryosuke Watanabe  1 , Masayuki Higashino  1 , Momoko Tsuda  1 , Mototsugu Kato  1
Affiliations
Case Reports

Oxaliplatin-Associated Amaurosis Fugax

Kimitoshi Kubo et al. Case Rep Oncol. .

Abstract

Oxaliplatin-associated amaurosis fugax has not been reported, and its clinical course and treatment remain largely unclear. A 70-year-old man with advanced gastric cancer was treated with the SOX regimen. After cycle 1 of oxaliplatin infusion, the patient realized that his right eye had visual field impairment, which he described as darkening of the right half of his visual field and loss of vision lasting about 1 min and occurring about 7 times a day. The daily frequency of this occurrence gradually decreased, and his visual field impairment improved in 1 week. However, as the same symptoms recurred from cycle 2 to cycle 5 of treatment, oxaliplatin was discontinued from cycle 6 and switched to S-1 monotherapy. Subsequently, the patient's amaurosis fugax improved. To our knowledge, this is the first report describing clinical course and treatment of oxaliplatin-associated amaurosis fugax.

Keywords: Amaurosis fugax; Ocular toxicity; Oxaliplatin; S-1 + oxaliplatin.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose in association with this study.

Figures

Fig. 1
Fig. 1
CT findings. CT revealed thickening of the gastric wall from the gastric body to the prepyloric region as well as retention of food residues. CT, computed tomography.
Fig. 2
Fig. 2
Endoscopic findings and a histopathological examination of the biopsy specimens. a EGD revealed friable and irregular mucosa, and a depressed lesion extending from the gastric antrum to the lower body. b Histopathological examination of biopsy specimens showed poorly differentiated adenocarcinoma (por) (×400) (scale bar, 50 μm). EGD, esophagogastroduodenoscopy.
Fig. 3
Fig. 3
MRI findings. a, b MRI showed no abnormal findings in the brain or around the orbit. c 3D-MRI showed no stenosis or aneurysm in the internal carotid artery or ophthalmic artery. MRI, magnetic resonance imaging.
See this image and copyright information in PMC

References

    1. Simpson D, Dunn C, Curran M, Goa KL. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs. 2003;63:2127–56. - PubMed
    1. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in cheotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015;26:141–8. - PubMed
    1. Wilkes GM. Therapeutic options in the management of colon cancer: 2005 update. Clin J Oncol Nurs. 2005;9:31–44. - PubMed
    1. O'Dea D, Handy CM, Wexler A. Ocular changes with oxaliplatin. Clin J Oncol Nurs. 2006;10:227–9. - PubMed
    1. Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic chemotherapy. Surv Ophthalmol. 1989;34:209–30. - PubMed

Publication types